ResultsIQ

ResultsIQ › Latest results › Suraksha Diagnostic Limited

Suraksha Diagnostic Limited Q2 FY27 results deck summary

NSE: SURAKSHA · BSE: 544293

Results deck of 12 Nov 2026, summarised by AI from the filing.

Suraksha Diagnostic's Q2 FY27 total income rose 26.38% to ₹1,005.75 mn with EBITDA margin of 36.7% and PAT of ₹149.50 mn.

Key takeaways

  1. FY27 expansion Three hubs and six spokes launched till date in FY27, with four hubs and seven spokes upcoming.
  2. Genomics Genomics revenue rose 115% year-on-year to ₹14.6 mn in Q2 FY27, lifting revenue per patient with limited incremental capex.

Original filing on BSE

Suraksha Diagnostic Limited Q2 FY27 results

As filed: Revenue ₹99.1 cr (+25% year on year), EBITDA ₹34.8 cr (+45% year on year), PAT ₹15.0 cr (+66% year on year), EBITDA margin 35.2% (+477 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹87.7 cr (+20% year on year), EBITDA ₹30.4 cr (+32% year on year), PAT ₹12.9 cr (+43% year on year), EBITDA margin 34.7% (+322 bps). Score 79 of 100, Above trend. EBITDA margin rose 322 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +19.8% in 30 days (Nifty 500: −3.4%).
  • Q4 FY26: Revenue ₹81.4 cr (+25% year on year), EBITDA ₹24.4 cr (+28% year on year), PAT ₹6.2 cr (−12% year on year), EBITDA margin 29.9% (+70 bps). Score 56 of 100, In line with trend. EBITDA margin rose 70 bps year on year. Tax rate 38%. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: −16.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹77.7 cr (+29% year on year), EBITDA ₹23.2 cr (+29% year on year), PAT ₹7.2 cr (+21% year on year), EBITDA margin 29.8% (−19 bps). Score 70 of 100, Above trend. EBITDA margin fell 19 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −9.7% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹79.0 cr (+18% year on year), EBITDA ₹24.0 cr (0% year on year), PAT ₹9.0 cr (−10% year on year), EBITDA margin 30.4% (−544 bps). Score 36 of 100, Below trend. EBITDA margin fell 544 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −13.0% in 30 days (Nifty 500: −0.8%).
  • Q1 FY26: Revenue ₹70.0 cr, EBITDA ₹24.0 cr, PAT ₹10.0 cr, EBITDA margin 34.3%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹64.0 cr, EBITDA ₹20.0 cr, PAT ₹8.0 cr, EBITDA margin 31.3%. Not scored. No result for the same quarter last year. Share price after the results: −1.7% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹59.0 cr, EBITDA ₹18.0 cr, PAT ₹6.0 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Suraksha Diagnostic Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.